Codexis Inc
NASDAQ:CDXS

Watchlist Manager
Codexis Inc Logo
Codexis Inc
NASDAQ:CDXS
Watchlist
Price: 4.61 USD 6.47% Market Closed
Market Cap: 375.2m USD
Have any thoughts about
Codexis Inc?
Write Note

Codexis Inc
Inventory

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Codexis Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Codexis Inc
NASDAQ:CDXS
Inventory
$2.1m
CAGR 3-Years
24%
CAGR 5-Years
39%
CAGR 10-Years
1%
Thermo Fisher Scientific Inc
NYSE:TMO
Inventory
$5.4B
CAGR 3-Years
3%
CAGR 5-Years
10%
CAGR 10-Years
11%
Danaher Corp
NYSE:DHR
Inventory
$2.7B
CAGR 3-Years
-1%
CAGR 5-Years
6%
CAGR 10-Years
4%
Mettler-Toledo International Inc
NYSE:MTD
Inventory
$375.8m
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
6%
Agilent Technologies Inc
NYSE:A
Inventory
$978m
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
-1%
IQVIA Holdings Inc
NYSE:IQV
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Codexis Inc
Glance View

Market Cap
375.1m USD
Industry
Life Sciences Tools & Services

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 261 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in discovering, developing and sells enzymes and other proteins. The company operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The firm has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. Its products include biocatalysts, chemical intermediates and Codex biocatalyst panels and kits. The company also commercialized three additional enzymes, such as Codex HiFi DNA Polymerase for use in next generation sequencing, Codex HiTemp Reverse Transcriptase for use in molecular diagnostic applications, and Codex HiCap RNA Polymerase for use in RNA synthesis applications. The firm is developing its lead program, CDX-6114 for the treatment of hyperphenylalaninemia (HPA).

CDXS Intrinsic Value
2.92 USD
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Codexis Inc's Inventory?
Inventory
2.1m USD

Based on the financial report for Sep 30, 2024, Codexis Inc's Inventory amounts to 2.1m USD.

What is Codexis Inc's Inventory growth rate?
Inventory CAGR 10Y
1%

Over the last year, the Inventory growth was -9%. The average annual Inventory growth rates for Codexis Inc have been 24% over the past three years , 39% over the past five years , and 1% over the past ten years .

Back to Top